Cover Image

Editorial: Erythropoietin and Its Analogues as Therapeutics for Neurological Diseases

Saved in:

Bibliographic Details
Main Authors:	Michael Brines (Author), Stephana Carelli (Author), Michele Samaja (Author), Edith M. Schneider Gasser (Author)
Format:	Book
Published:	Frontiers Media S.A., 2022-02-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Mitochondrial Metabolism as Target of the Neuroprotective Role of Erythropoietin in Parkinson's Disease
by: Federica Rey, et al.
Published: (2021)

Study of lncRNAs in Pediatric Neurological Diseases: Methods, Analysis of the State-of-Art and Possible Therapeutic Implications
by: Cecilia Pandini, et al.
Published: (2023)

Erythropoietin Produces a Dual Effect on Carotid Body Chemoreception in Male Rats
by: Christian Arias-Reyes, et al.
Published: (2021)

Oleanolic acid and its analogues: promising therapeutics for kidney disease
by: Dan Pan, et al.
Published: (2024)

Can Erythropoietin Reduce Hypoxemic Neurological Damages in Neonates With Congenital Heart Defects?
by: Sara Ottolenghi, et al.
Published: (2021)

Editorial: Novel therapeutic target and drug discovery for neurological diseases
by: Kaiyue Zhao, et al.
Published: (2022)

Addressing the 'hypoxia paradox' in severe COVID-19: literature review and report of four cases treated with erythropoietin analogues
by: Martin Begemann, et al.
Published: (2021)

Editorial: Combined Therapeutic Approaches to Neurological Rehabilitation
by: Elizabeth Rochon, et al.
Published: (2022)

Editorial: The digitalization of neurology
by: Daniel B. Hier, et al.
Published: (2023)

Editorial: Prescription and execution of therapeutic exercise programs in neurological disorders
by: J. Güeita-Rodríguez, et al.
Published: (2022)

Editorial " Hypoxia and reoxygenation: from basic science to bedside
by: Michele eSamaja, et al.
Published: (2015)

Therapeutic Potential and Immunomodulatory Role of Coenzyme Q<sub>10</sub> and Its Analogues in Systemic Autoimmune Diseases
by: Chary López-Pedrera, et al.
Published: (2021)

Editorial: Natural products in the treatment of neurological diseases: identification of novel active compounds and therapeutic targets
by: Jia Zhao, et al.
Published: (2023)

Suppression of Coronary Atherosclerosis by Helix B Surface Peptide, a Nonerythropoietic, Tissue-Protective Compound Derived from Erythropoietin
by: Hiroto Ueba, et al.
Published: (2013)

Editorial: Assessing the Pharmacological Effects and Therapeutic Potential of Traditional Chinese Medicine in Neurological Disease Models: An Update
by: Zhiqiang Deng, et al.
Published: (2022)

Editorial: Natural Products-Based Drugs: Potential Therapeutics Against Alzheimer's Disease and Other Neurological Disorders
by: Muhammad Ayaz, et al.
Published: (2019)

The therapeutic potential of triptolide and celastrol in neurological diseases
by: Yueran Cui, et al.
Published: (2022)

THERAPEUTIC PEDAGOGY IN NEUROLOGICAL AND MENTAL DISEASES OF CHILDREN
by: R.V. Lashko
Published: (2008)

Editorial: ICF-based rehabilitation for neurological disease
by: Clynton L. Correa, et al.
Published: (2022)

The erythropoietin‐derived peptide ARA 284 reduces tissue wasting and improves survival in a rat model of cancer cachexia
by: Sandra Palus, et al.
Published: (2022)

Redox Imbalance in Neurological Disorders in Adults and Children
by: Federica Rey, et al.
Published: (2023)

Erythropoietin: from erythropoiesis to cardioprotection
by: Liermis Michael Dita Salabert, et al.
Published: (2010)

Erythropoietin: from erythropoiesis to cardioprotection
by: Liermis Michael Dita Salabert, et al.
Published: (2010)

Pleiotropic effects of Erythropoietin. Influence of Erythropoietin on processes of mesenchymal stem cells differentiation
by: Ekaterina V. Zubareva, et al.
Published: (2019)

ERYTHROPOIETIN AS DOPING AGENT
by: Nina Đukanović, et al.
Published: (2012)

Therapeutic potential for KCC2-targeted neurological diseases
by: Kazuo Tomita, et al.
Published: (2023)

Human Endogenous Retrovirus as Therapeutic Targets in Neurologic Disease
by: Karen Giménez-Orenga, et al.
Published: (2021)

Predictors of hyporesponsiveness to erythropoietin in prevalent hemodialysis patients and its association with mortality
by: Marisa Roldão, et al.
Published: (2022)

Topical erythropoietin as a novel preventive and therapeutic agent in bisphosphonate-related osteonecrosis of the jaw
by: Pantea Nazeman, et al.
Published: (2016)

Biomimetic carbon nanotubes for neurological disease therapeutics as inherent medication
by: Chenyang Xiang, et al.
Published: (2020)

Monoclonal Antibodies as Neurological Therapeutics
by: Panagiotis Gklinos, et al.
Published: (2021)

Coenzyme Q<sub>10</sub> Analogues: Benefits and Challenges for Therapeutics
by: Juan M. Suárez-Rivero, et al.
Published: (2021)

The Effect of Erythropoietin and Its Derivatives on Ischemic Stroke Therapy: A Comprehensive Review
by: Yuanyuan Ma, et al.
Published: (2022)

Regulation of muscle and metabolic physiology by hypothalamic erythropoietin independently of its peripheral action
by: Zhouguang Wang, et al.
Published: (2020)

Pyrimidine analogues for the management of neurodegenerative diseases
by: Swati Pant, et al.
Published: (2022)

Dynamics of Erythroferrone Response to Erythropoietin in Rats
by: Peng Xu, et al.
Published: (2022)

Scaling Pharmacodynamics from Rats to Humans to Support Erythropoietin and Romiplostim Combination Therapy to Treat Erythropoietin-Resistant Anemia
by: Xiaoqing Fan, et al.
Published: (2023)

Therapeutic efficacy evaluation of the reference drug ursodeoxycholic acid and its analogues in the biliary sludge dissolution: a meta-analysis
by: Yury A. Kucheryavyy, et al.
Published: (2023)

Non-hematopoietic erythropoietin-derived peptides for atheroprotection and treatment of cardiovascular diseases
by: Veronika S. Belyaeva, et al.
Published: (2020)

Stability of erythropoietin repackaging in polypropylene syringes for clinical use
by: Angela Marsili, et al.
Published: (2017)